Systemic sclerosis has two major forms: limited cutaneous systemic sclerosis, where skin thickening stays below the elbows and knees (and on the face), and diffuse cutaneous systemic sclerosis, where it extends to the upper arms, thighs, or trunk. The distinction is far more than skin-deep. It predicts which internal organs are most at risk, how fast the disease moves, which autoantibodies are typically present, and what monitoring schedule can catch complications early. Understanding your subtype is the foundation of a modern scleroderma care plan.One clarification first: localized scleroderma (morphea and linear scleroderma) affects patches of skin only, does not involve internal organs, and is a different disease from systemic sclerosis. This article covers the systemic forms. Limited Cutaneous Systemic Sclerosis Limited disease, the more common subtype, tends to move slowly, often after years of Raynaud’s phenomenon alone.Skin involvement: fingers, hands, forearms, lower legs, and face; spares the trunkTypical antibody: anti-centromerePace: gradual, over yearsSignature risk: pulmonary arterial hypertension (PAH), elevated pressure in the lung arteries, which can develop late in the disease course, making lifelong annual echocardiogram screening essentialOther features: prominent telangiectasias, calcinosis, severe Raynaud’s with fingertip ulcers, esophageal reflux What Is CREST Syndrome? CREST is an older name still widely used for limited systemic sclerosis, describing its five hallmark features:Calcinosis: calcium deposits under the skinRaynaud’s phenomenonEsophageal dysmotility: reflux and swallowing difficultySclerodactyly: tight, thickened finger skinTelangiectasia: small dilated blood vessels on hands and facePhysicians today generally say “limited cutaneous systemic sclerosis” because patients don’t need all five features, and because the …
Limited vs. Diffuse Systemic Sclerosis: Types, CREST Syndrome, and Today’s Treatment Options
Systemic sclerosis has two major forms: limited cutaneous systemic sclerosis, where skin thickening stays below the elbows and knees (and on the face), and diffuse cutaneous systemic sclerosis, where it extends to the upper arms, thighs, or trunk. The distinction is far more than skin-deep. It predicts which internal organs are most at risk, how fast the disease moves, which autoantibodies are typically present, and what monitoring schedule can catch complications early. Understanding your subtype is the foundation of a modern scleroderma care plan.
One clarification first: localized scleroderma (morphea and linear scleroderma) affects patches of skin only, does not involve internal organs, and is a different disease from systemic sclerosis. This article covers the systemic forms.
Limited Cutaneous Systemic Sclerosis
Limited disease, the more common subtype, tends to move slowly, often after years of Raynaud’s phenomenon alone.
- Skin involvement: fingers, hands, forearms, lower legs, and face; spares the trunk
- Typical antibody: anti-centromere
- Pace: gradual, over years
- Signature risk: pulmonary arterial hypertension (PAH), elevated pressure in the lung arteries, which can develop late in the disease course, making lifelong annual echocardiogram screening essential
- Other features: prominent telangiectasias, calcinosis, severe Raynaud’s with fingertip ulcers, esophageal reflux
What Is CREST Syndrome?
CREST is an older name still widely used for limited systemic sclerosis, describing its five hallmark features:
- Calcinosis: calcium deposits under the skin
- Raynaud’s phenomenon
- Esophageal dysmotility: reflux and swallowing difficulty
- Sclerodactyly: tight, thickened finger skin
- Telangiectasia: small dilated blood vessels on hands and face
Physicians today generally say “limited cutaneous systemic sclerosis” because patients don’t need all five features, and because the name CREST can falsely suggest a purely cosmetic condition, when PAH and other internal complications remain real risks.
Diffuse Cutaneous Systemic Sclerosis
Diffuse disease is less common but moves faster and demands tighter surveillance, especially in the first three to five years.
- Skin involvement: extends above elbows and knees to upper arms, thighs, chest, or abdomen; often rapid early progression
- Typical antibodies: anti-Scl-70 (topoisomerase I), associated with lung fibrosis, or anti-RNA polymerase III, associated with renal crisis
- Pace: skin and organ involvement can evolve within months
- Signature risks: interstitial lung disease (ILD), meaning inflammation and scarring of the lungs, and scleroderma renal crisis, an abrupt, severe rise in blood pressure with kidney injury
- Other features: early tendon friction rubs, joint contractures, muscle involvement, fatigue and weight loss
Side by Side
| Feature | Limited SSc | Diffuse SSc |
|---|---|---|
| Skin thickening | Below elbows/knees + face | Also upper arms, thighs, trunk |
| Onset pattern | Slow; long Raynaud’s prelude | Rapid; Raynaud’s and skin changes close together |
| Typical antibody | Anti-centromere | Anti-Scl-70 or anti-RNA polymerase III |
| Top organ risk | Pulmonary arterial hypertension (late) | Lung fibrosis and renal crisis (early) |
| Monitoring emphasis | Annual echocardiogram, PFTs | Frequent PFTs, HRCT, blood pressure & kidney checks |
| Old name | CREST syndrome | (none) |
limited disease demands patience and lifelong vigilance for PAH; diffuse disease demands urgency and intensive early monitoring. Neither subtype is “mild.” They’re just dangerous in different ways and on different clocks.
Treatment in 2026: Organ-Targeted and Increasingly Effective
There is no single drug that “treats scleroderma.” Modern care pairs subtype-based monitoring with organ-specific therapy, and the toolbox has grown meaningfully:
- Interstitial lung disease: mycophenolate remains a first-line immunosuppressant; nintedanib (an antifibrotic) is FDA-approved to slow SSc-ILD progression; tocilizumab (IL-6 blockade) is approved to preserve lung function in early inflammatory disease.
- Pulmonary arterial hypertension: multiple approved vasodilator classes (endothelin receptor antagonists, PDE-5 inhibitors, prostacyclin pathway agents), often used in combination, with the best results when PAH is caught early by screening.
- Raynaud’s and digital ulcers: calcium channel blockers first-line; PDE-5 inhibitors and other vasodilators for severe disease and ulcer prevention.
- Reflux and gut involvement: proton pump inhibitors, motility strategies, and nutrition support when needed.
- Renal crisis: prompt ACE-inhibitor treatment has transformed outcomes, and is why home blood-pressure monitoring is standard advice in diffuse disease.
- Rapidly progressive disease: autologous stem cell transplantation has demonstrated durable benefit in carefully selected patients; CAR-T and other cell-based approaches are in active trials and represent the field’s current frontier.
Frequently Asked Questions
CREST syndrome is an older name for limited cutaneous systemic sclerosis, one of the two main forms of scleroderma. The term describes five hallmark features (calcinosis, Raynaud’s, esophageal dysmotility, sclerodactyly, telangiectasia), but patients don’t need all five for the diagnosis.
Diffuse systemic sclerosis generally carries higher early risk. Lung fibrosis and kidney crisis can develop within the first few years. But limited disease is not benign: pulmonary arterial hypertension can emerge decades in, which is why lifelong screening matters for both subtypes.
Autoantibodies align strongly with subtype: anti-centromere with limited disease, anti-Scl-70 with diffuse disease and lung fibrosis risk, and anti-RNA polymerase III with rapid skin progression and renal crisis risk. Antibody results help set each patient’s monitoring schedule.
Subtype generally remains stable. Limited disease rarely converts to diffuse. However, internal organ involvement can still progress within each subtype, so classification never substitutes for ongoing organ monitoring.
A Monitoring Plan Matched to Your Subtype. This Week, Not Next Season.
Whether your disease is limited or diffuse, outcomes track with how early complications are caught. Dr. Dhillon, a board-certified rheumatologist, sees new patients by secure video visit from your home, usually within the same week, with your complete records reviewed before the visit and direct texting access between appointments. No referral required. Video visits are available to patients located in California, with in-person care in Beverly Hills.
Book a Video Visit, or call for a 15 minute discovery call at +1 (949) 209-4716.
This article is for educational purposes and is not a substitute for personalized medical advice, diagnosis, or treatment. Always consult a qualified physician about your specific situation.
